Obesity

December 5th 2024

A proposal from the Biden administration to provide coverage of weight loss drugs through Medicaid and Medicare may cost more than it saves.

November 26th 2024

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.

November 25th 2024

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.

November 21st 2024

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.